Cargando…
In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium
Infections with carbapenem-resistant (CR) Gram-negative (GN) pathogens have increased in many countries worldwide, leaving only few therapeutic options. Cefiderocol (CFDC) is approved in Europe for the treatment of aerobic GN infections in adults with limited treatment options. This study evaluated...
Autores principales: | Oueslati, Saoussen, Bogaerts, Pierre, Dortet, Laurent, Bernabeu, Sandrine, Ben Lakhal, Hend, Longshaw, Christopher, Glupczynski, Youri, Naas, Thierry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598183/ https://www.ncbi.nlm.nih.gov/pubmed/36290010 http://dx.doi.org/10.3390/antibiotics11101352 |
Ejemplares similares
-
Population Analysis of Escherichia coli Sequence Type 361 and Reduced Cefiderocol Susceptibility, France
por: Jousset, Agnès B., et al.
Publicado: (2023) -
To Be or Not to Be an OXA-48 Carbapenemase
por: Dabos, Laura, et al.
Publicado: (2022) -
In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in France
por: Naas, Thierry, et al.
Publicado: (2021) -
Optimization of the MALDIxin test for the rapid identification of colistin resistance in Klebsiella pneumoniae using MALDI-TOF MS
por: Dortet, Laurent, et al.
Publicado: (2020) -
Erratum to: In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in France
por: Naas, Thierry, et al.
Publicado: (2021)